Thursday, 20 February 2020

Glenmark receives ANDA approval for Aspirin and generic version of Aggrenox® Capsules

27 May 2019 | News

Glenmark’s current portfolio consists of 155 products authorized for distribution in the U.S. marketplace

Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, a generic version of Aggrenox® Capsules, 25 mg/200 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.

According to IQVIATM sales data for the 12 month period ending March 2019, the Aggrenox® Capsules, 25 mg/200 mg market2 achieved annual sales of approximately $165.6 million.

Glenmark’s current portfolio consists of 155 products authorized for distribution in the U.S. marketplace and 57 ANDA’s pending approval with the U.S. FDA.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account